Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.

Carla PreziosoAlfonso GrimaldiDoriana LandiCarolina Gabri NicolettiGabriele BrazziniFrancesca PiacentiniSara PasseriniDolores LimongiCaterina SagnelliAnna Teresa PalamaraGirolama Alessandra MarfiaValeria Pietropaolo

Published in: Viruses (2021)

Ocrelizumab in JCPyV-DNA positive patients is safe and did not determine PML cases. Combined monitoring of ocrelizumab's effects on JCPyV pathogenicity and on host immunity might offer a complete insight towards predicting PML risk.

Keyphrases

multiple sclerosis
end stage renal disease
risk assessment
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
escherichia coli
human health
smoking cessation